Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 13;43(1):144-160.e7.
doi: 10.1016/j.ccell.2024.11.012. Epub 2024 Dec 12.

Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host

Affiliations

Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host

Maria F Gonzalez-Aponte et al. Cancer Cell. .

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults with a poor prognosis despite aggressive therapy. Here, we hypothesized that daily host signaling regulates tumor growth and synchronizes circadian rhythms in GBM. We find daily glucocorticoids promote or suppress GBM growth through glucocorticoid receptor (GR) signaling depending on time of day and the clock genes, Bmal1 and Cry. Blocking circadian signals, like vasoactive intestinal peptide or glucocorticoids, dramatically slows GBM growth and disease progression. Analysis of human GBM samples from The Cancer Genome Atlas (TCGA) shows that high GR expression significantly increases hazard of mortality. Finally, mouse and human GBM models have intrinsic circadian rhythms in clock gene expression in vitro and in vivo that entrain to the host through glucocorticoid signaling, regardless of tumor type or host immune status. We conclude that GBM entrains to the circadian circuit of the brain, modulating its growth through clock-controlled cues, like glucocorticoids.

Keywords: Bmal1; TMZ; VIP; cancer neuroscience; circadian rhythms; clock genes; dexamethasone; glioblastoma; glucocorticoids; period gene; temozolomide; vasoactive intestinal peptide.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Update of

References

    1. Tamimi AF, and Juweid M (2017). Epidemiology and Outcome of Glioblastoma. In Glioblastoma, De Vleeschouwer S, ed. (Codon Publications; ). - PubMed
    1. Cancer of the Brain and Other Nervous System - Cancer Stat Facts SEER. https://seer.cancer.gov/statfacts/html/brain.html.
    1. Fernandes C, Costa A, Osório L, Lago RC, Linhares P, Carvalho B, and Caeiro C (2017). Current Standards of Care in Glioblastoma Therapy. In Glioblastoma, De Vleeschouwer S, ed. (Codon Publications; ). - PubMed
    1. Hottinger AF, Pacheco P, and Stupp R (2016). Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol 18, 1338–1349. 10.1093/neuonc/now182. - DOI - PMC - PubMed
    1. Slat EA, Sponagel J, Marpegan L, Simon T, Kfoury N, Kim A, Binz A, Herzog ED, and Rubin JB (2017). Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma. J Biol Rhythms 32, 121–129. 10.1177/0748730417696788. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources